Relevant bibliographies by topics / Evolocumab

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Evolocumab'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Evolocumab.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Evolocumab"

1

McKenna, Louise, Gerry McKay, and Miles Fisher. "Evolocumab." Practical Diabetes 34, no. 9 (2017): 329–30. http://dx.doi.org/10.1002/pdi.2148.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vural, Elif Hilal, Ensar Korkut Kılıc, Enver Kağan Atikeler, and Bülent Gümüşel. "TURKISH EXAMPLE OF PRIORITIZATION AND RESTRICTION DECISIONS IN MEDICINE ACCESS: EVALUATION BASED ON TWO INNOVATIVE DRUGS." Ankara Universitesi Eczacilik Fakultesi Dergisi 48, no. 3 (2024): 35. http://dx.doi.org/10.33483/jfpau.1525060.

Full text
Abstract:
Objective: Drug licensing, price, and reimbursement are essential for medical access. This study examines US, EU, and Turkish reimbursement for innovative medicines and evaluates Türkiye's recent licensing and reimbursement decisions. Material and Method: Nivolumab, an anticancer medicine, and Evolocumab, a hyperlipidemia treatment, were studied. Web-based searches of FDA, EMA, and TİTCK offical websites revealed authorized indications and approval dates for chosen medications. Result and Discussion: Nivolumab has been authorized for 11 indications by the FDA and 10 by the EMA, although it is
APA, Harvard, Vancouver, ISO, and other styles
3

Laluyan, Kristiani A., Edward Nangoy, and Jimmy Posangi. "Pengaruh Evolocumab terhadap Pasien Dislipidemia dengan Intoleransi Statin." e-CliniC 12, no. 1 (2023): 87–95. http://dx.doi.org/10.35790/ecl.v12i1.45494.

Full text
Abstract:
Abstract: Statins, lipid-lowering drugs, are used to reduce low density lipoprotein cholesterol (LDL-C). Although statins are well tolerated by most people, their side effects e. g. myopathy and statin intolerance have impacts on dose reduction and therapy discontinuation. Evolocumab is considered in patients with statin intolerance. This study aimed to determine the effect of evolocumab on LDL-C levels in patients with dyslipidemia and statin intolerance. This was a literature review study using literature search on three databases, namely PubMed, ClinicalKey, and ScienceDirect with the keywo
APA, Harvard, Vancouver, ISO, and other styles
4

Al Faraidy, Khalid, Mousa Akbar, Mohamed Shehri, et al. "Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study." PLOS ONE 18, no. 1 (2023): e0278821. http://dx.doi.org/10.1371/journal.pone.0278821.

Full text
Abstract:
Objectives Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice. Methods ZERBINI was a multi-country, observational, retrospective/prospective study of subjects receiving evolocumab as part of routine clinical management of their hyperlipidemia. This regional publication reports on adult participants from Saudi Arabia and Kuwait who have had ≥1 dose of evolocumab before enrollment and ≤6 months’ prior exposure t
APA, Harvard, Vancouver, ISO, and other styles
5

Cebova, Martina, Radoslava Bulkova, and Olga Pechanova. "Evolocumab Reduces Oxidative Stress and Lipid Peroxidation in Obese Zucker Rats." Pathophysiology 32, no. 1 (2025): 5. https://doi.org/10.3390/pathophysiology32010005.

Full text
Abstract:
Background/Objectives: Evolocumab inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) binding to low-density lipoprotein (LDL) receptors, thus allowing more LDL receptors to remove LDL cholesterol from the blood. We aimed to determine the effects of evolocumab on the plasma lipid profile, reactive oxygen species (ROS), and nitric oxide (NO) generation in the heart of adult male obese Zucker rats. Methods: The rats were divided into lean and obese controls and obese rats treated with evolocumab subcutaneously at a dose of 10 mg/kg every two weeks. After 6 weeks, the lipid profile was
APA, Harvard, Vancouver, ISO, and other styles
6

Hirai, Keiji, Shigeki Imamura, Aizan Hirai, Susumu Ookawara, and Yoshiyuki Morishita. "Effects of Evolocumab on Carotid Intima-Media Thickness and Clinical Parameters in Patients Taking a Statin." Journal of Clinical Medicine 9, no. 7 (2020): 2256. http://dx.doi.org/10.3390/jcm9072256.

Full text
Abstract:
We determined the effects of evolocumab, a fully human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9, on carotid intima-media thickness (IMT) and the factors associated with the change in carotid IMT in patients taking a statin. The change in carotid mean and maximum IMT before and after the initiation of evolocumab treatment was retrospectively analyzed in 229 statin-treated patients. The changes in clinical parameters, including serum lipid concentrations, were also evaluated. Evolocumab significantly reduced the increase in carotid mean and maximum IMT (0.09 ±
APA, Harvard, Vancouver, ISO, and other styles
7

Okada, Tomoaki, Toru Miyoshi, Masayuki Doi, et al. "Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial." Journal of Cardiovascular Development and Disease 9, no. 5 (2022): 153. http://dx.doi.org/10.3390/jcdd9050153.

Full text
Abstract:
Elevated circulating lipoprotein(a) levels are associated with an increased risk of cardiovascular events. We reported that early initiation of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in addition to a statin substantially reduced the lipoprotein(a) levels in patients with acute myocardial infarction (AMI) after primary percutaneous coronary intervention (PCI). This sub-analysis sought to investigate the effect of evolocumab on lipoprotein(a) based on baseline lipoprotein(a) levels and characteristics. This study was a prespecified analysis of a randomized control
APA, Harvard, Vancouver, ISO, and other styles
8

Gokul, S.*, and P. Rama Dr. "EVALUATING THE SAFETY OF EVOLOCUMAB IN CARDIOVASCULAR DISEASE." World Journal of Pharmaceutical Science and Research 3, no. 5 (2024): 175–81. https://doi.org/10.5281/zenodo.13870904.

Full text
Abstract:
Evolocumab is a ground breaking monoclonal antibody that plays a crucial role in managing cardiovascular disease by targeting PCSK9, a protein involved in cholesterol regulation. By inhibiting PCSK9, evolocumab enhances the liver's ability to clear LDL cholesterol, effectively reducing cardiovascular events. This powerful LDL-lowering mechanism is especially advantageous for patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) who do not respond well to standard treatments. Clinical studies, such as the FOURIER trial, have shown that
APA, Harvard, Vancouver, ISO, and other styles
9

Podolec, Jakub, and Lukasz Niewiara. "Guest Editorial Commentary on the Findings of the GLAGOV Randomized Clinical Trial." US Cardiology Review 11, no. 1 (2017): 18. http://dx.doi.org/10.15420/usc.11.1.ge.

Full text
Abstract:
Evolocumab – a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) – significantly reduces low-density lipoprotein cholesterol levels. This agent has been tested in a series of clinical trials, one of which is discussed here: the GLAGOV study. Statintreated patients with coronary disease were treated with evolocumab or placebo with the result that patients in the evolocumab group low-density lipoprotein cholesterol (LDL-C) levels were significantly lower than the placebo group. Athersclerotic plaque regression was noticed in greater number of patients
APA, Harvard, Vancouver, ISO, and other styles
10

Srinivasan, Sneha. "Use of the PCSK9 inhibitor, evolocumab, in patients with heterozygous familial hypercholesterolemia." MOJ Public Health 8, no. 5 (2019): 156–60. http://dx.doi.org/10.15406/mojph.2019.08.00301.

Full text
Abstract:
Evolocumab is a monoclonal immunoglobulin G2 that acts against human proprotein convertase subtilisin/kexin type 9 (PCK9) used against Homozygous familial hypercholesterolemia and Heterozygous familial hypercholesterolemia in high cardiovascular disease risk patients with increased level of triglycerides. Evolocumab is administered subcutaneously 420mg every month and 140 mg twice a week in patients with HeFH as evaluated by RUTHERFORD and RUTHERFORD 2 trials. This paper reviews the six clinical trials of evolocumab that evaluated the efficacy of the drug for heterogenous familial hypercholest
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Evolocumab"

1

Svensson, Henrik. "Ldl-sänkande läkemedelsbehandling för hjärtinfarktpatienter - är nuvarande behandlingsriktlinjer rimliga?" Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2018. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-74501.

Full text
Abstract:
Sammanfattning Bakgrund Insjuknande i hjärtinfarkt har minskat kraftigt i Sverige de senaste åren men drabbar fortfarande många. Ateroskleros i hjärtats kranskärl är den viktigaste bakomliggande orsaken. Utvecklingen av ateroskleros sker under lång tid och processen är komplex men kan kopplas till inflammatoriska processer, apoB-innehållande lipoprotein och endoteldysfunktion. LDL bedöms av många forskare vara en kausal faktor vid aterosklersutvecklingen. Denna bedömning grundar sig på djurförsök, observationsstudier, resultat från kliniska prövningar med LDL-sänkande läkemedel samt mendelska
APA, Harvard, Vancouver, ISO, and other styles
2

Molin, Tor. "Evolokumabs effekt och kostnadseffektivitet hos patienter utan familjär kolesterolemi." Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-85420.

Full text
Abstract:
Atherosclerosis is the underlying cause for many serious cardiovascular diseases which causes over 50 % of all deaths in Sweden. Atherosclerotic plaque builds up in the vessel walls over decades that will eventually lead to a complete block of an artery or cause thrombosis when the plaque ruptures, this leads to myocardial infarction and stroke. A major contributing factor to the buildup of plaque is cholesterol, especially low density lipoprotein, LDL. LDL can oxidize and start an inflammation process and together with cells from the immune system form the basis for a plaque. Proprotein conve
APA, Harvard, Vancouver, ISO, and other styles
3

Fahey, Kelly Marie. "The efficacy and cost-effectiveness of evolocumab in the prevention of cardiovascular disease." Thesis, 2018. https://hdl.handle.net/2144/33009.

Full text
Abstract:
Heart disease is the leading cause of death in the United States. Hyperlipidemia is a predominant risk factor in the development of atherosclerotic cardiovascular disease (ASCVD). The statin drug class is the first line therapeutic for lowering atherogenic low-density lipoprotein (LDL) levels by competitively inhibiting 3-hydroxyl-3methyl-glutaryl-coenzyme A (HMGCR) reductase, the rate-limiting enzyme in cholesterol biosynthesis. However, there are patients who are unable to achieve desirable LDL levels despite statin therapy, such as those with familial hypercholesterolemia or those who ar
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Evolocumab"

1

"Evolocumab." In Hale’s Medications & Mothers’ Milk™ 2019. Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.0385.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Morales-Villegas, Enrique C., and Kausik K. Ray. "PCSK9 Inhibition with Evolocumab Reaching Physiologic LDL-C Levels for Reducing Atherosclerotic Burden and Cardiovascular Disease-The Full Landscape." In Frontiers in Cardiovascular Drug Discovery: Volume 4. BENTHAM SCIENCE PUBLISHERS, 2019. http://dx.doi.org/10.2174/9781681083995118040007.

Full text
Abstract:
Physiologically, in the presence of an intracellular deficit of cholesterol, the LDLR synthesis, expression and function increase, thus uptaking and providing cholesterol to the cell. This process is counter-regulated by PCSK9 expression, the protease inducing LDLR proteolysis, thereby limiting its function maintaining a constant cholesterol intracellular concentration. Accordingly, the balance between PCSK9 and LDLR regulates the intracellular concentration of cholesterol and in consequence has impact on circulating LDL-cholesterol. This chapter reviews the brief and amazing recent history wi
APA, Harvard, Vancouver, ISO, and other styles
3

Pahlajani, Dev. "Efficacy and safety of evolocumab in reducing lipids and cardiovascular events." In Yearbook of Cardiology 2016. Jaypee Brothers Medical Publishers (P) Ltd., 2016. http://dx.doi.org/10.5005/jp/books/12834_63.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Albarrán Gómez, Andrea, Natalia Roso Jimenez, Ana Maria Lopez Gonzalez, et al. "Evaluación de la efectividad de evolocumab en vida real con perspectiva de género." In Libro de comunicaciones 69 Congreso SEFH. Sociedad Española de Farmacia Hospitalaria, 2024. http://dx.doi.org/10.62917/24.69.0419.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Blazquiz Ibero, Estela, Belen Rodrigo, Silvia Martinez, et al. "ANÁLISIS EN PRÁCTICA CLÍNICA REAL DE LOS RESULTADOS DE PACIENTES EN TRATAMIENTO CON EVOLOCUMAB." In Libro de comunicaciones 69 Congreso SEFH. Sociedad Española de Farmacia Hospitalaria, 2024. http://dx.doi.org/10.62917/24.69.0522.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Carrizo, Jose Ignacio, Macarena Comet, Isabel Puértolas, Natalia Allué, Carmen Viñuales, and Pilar Amador. "ESTUDIO DE LA EFICACIA Y SEGURIDAD DE ALIROCUMAB Y EVOLOCUMAB EN LA PRÁCTICA CLÍNICA REAL." In Libro de comunicaciones 69 Congreso SEFH. Sociedad Española de Farmacia Hospitalaria, 2024. http://dx.doi.org/10.62917/24.69.0313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rakhshanda, Shagoofa, Siaw-Teng Liaw, Joel Rhee, Kerry-Anne Rye, and Jitendra Jonnagaddala. "Strategies to Address Statin Medication Intolerance Among Patients at Risk of Cardiovascular Disease Identified Through Electronic Health Records: A Literature Review and Pooled Analysis." In Studies in Health Technology and Informatics. IOS Press, 2024. http://dx.doi.org/10.3233/shti240362.

Full text
Abstract:
Statins are a group of medications that lower lipid and are used for primary and secondary prevention of cardiovascular diseases (CVD). Patients can either be partially (15%) or completely (5%) intolerant to statins. Symptoms of statin intolerance can include muscle aches (myalgia), weakness, cramps, myopathy, diabetes mellitus, and elevated creatine kinase levels. Decreasing statin intolerance also improves statin adherence, which in turn results in lower number of CVD events among patients. Studies on statin intolerance is often embedded within studies of statin adherence. However, relevant
APA, Harvard, Vancouver, ISO, and other styles
8

COLLINS TAVELLA PAULINO, IAGO, ISABELLA LUTTERBACH ERTHAL, PEDRO ASSUMPÇÃO ARAUJO RODRIGUES DE SOUZA, SARAH QUICK LOURENÇO DE LIMA, and SOPHIA CALÁBRIA DA SILVEIRA. "EVOLOCUMABE: UMA OPÇÃO INOVADORA PARA O TRATAMENTO DA DOENÇA ARTERIAL CORONARIANA." In Cardiologia Teoria e Prática - Edição XI, 11th ed. Guilherme Barroso L. De Freitas, 2023. http://dx.doi.org/10.59290/978-65-6029-060-0.20.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Evolocumab"

1

Tent, Michiel. "Evolocumab improves coronary plaque morphology in stable CAD." In ACC 2023 Scientific Session, edited by Marc Bonaca. Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/edb21ce4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Domínguez Bachiller, M., MI Barcia Martin, AM Gomez Pedrero, and M. Perez Encinas. "4CPS-021 Alirocumab and evolocumab: results in clinical practice." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Serrano, M. Llorente, J. Sánchez Gundín, A. Rueda Naharro, C. Martí Gil, L. Martínez Valdivieso, and D. Barreda Hernández. "DI-016 Use of arilocumab and evolocumab: lipid lowering therapies." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.263.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Giles, Rachel. "Long-term therapy with evolocumab associated with lower CV mortality." In ESC Congress 2022, edited by Marc Bonaca. Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/07bc281c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Torres, P. Rovira, A. Jimenez Portilla, M. Ortiz Gonzalez, et al. "5PSQ-025 Real-world effectiveness and safety of evolocumab and alirocumab." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.379.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Villacañas Palomares, MV, A. Colón Lopez de Dicastillo, I. Gutiérrez Pérez, et al. "5PSQ-029 Effectiveness and safety of evolocumab in real clinical practice." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.462.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Monforte Gasque, MP, I. Varela Martínez, and CA Moncín Torres. "4CPS-029 Clinical experience of new lipid-lowering therapies: evolocumab and alirocumab." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.178.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Díez, B. Cancela, C. Muñoz, R. Claramunt, S. Guijarro, MJ Barbero, and F. Horno. "5PSQ-026 Efficacy and safety of evolocumab in hypercholesterolaemia and mixed dyslipidaemia." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.380.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bertran de lis Bartolome, B., M. González Sevilla, and JM Ferrari Piquero. "4CPS-022 Adherence to evolocumab and its impact on LDL cholesterol reduction." In 27th EAHP Congress, Lisbon, Portugal, 22-23-24 March 2023. British Medical Journal Publishing Group, 2023. http://dx.doi.org/10.1136/ejhpharm-2023-eahp.67.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

García Contreras, S., MD Edo Solsona, M. Rubio Almanza, et al. "4CPS-168 Effectiveness, safety and adherence to evolocumab in real clinical practice." In 28th EAHP Congress, Bordeaux, France, 20-21-22 March 2024. British Medical Journal Publishing Group, 2024. http://dx.doi.org/10.1136/ejhpharm-2024-eahp.272.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Evolocumab' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography